Accepted for Publication: July 13, 2022.
Published Online: August 31, 2022. doi:10.1001/jamacardio.2022.2847
Correction: This article was corrected on October 12, 2022, to fix the presentation of the author name W. Schuyler Jones.
Corresponding Author: Javed Butler, MD, MPH, MBA, Baylor Scott and White Research Institute, 3434 Live Oak St, Ste 501, Dallas, TX 75204 (javed.butler@bwshealth.org).
Author Contributions: Drs Harrington and Butler had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Harrington, Petrie, Bhatt, Jones, Hernandez, Butler.
Acquisition, analysis, or interpretation of data: Harrington, Anker, Bhatt, Jones, Udell, Butler.
Drafting of the manuscript: Harrington, Petrie, Butler.
Critical revision of the manuscript for important intellectual content: Harrington, Anker, Bhatt, Jones, Udell, Hernandez, Butler.
Administrative, technical, or material support: Hernandez.
Supervision: Petrie, Jones, Butler.
Conflict of Interest Disclosures: Dr Harrington reported salary support from T32 training grant T32HL069749. Dr Petrie reported grants from AstraZeneca, Boehringer Ingelheim, Novartis, Novo Nordisk, Vifor, and SQ Innovations; personal fees from AstraZeneca, Boehringer Ingelheim, Novartis, Novo Nordisk, Pharmacosmos, Bayer, Takeda, and SQ Innovations outside the submitted work; is supported by the British Heart Foundation Centre of Research Excellence Award; receives research funding from Boehringer Ingelheim, Roche, SQ Innovations, AstraZeneca, Novartis, Novo Nordisk, Medtronic, Boston Scientific, and Pharmacosmos; and serves as a consultant and on end point committees for Boehringer Ingelheim, Novartis, AstraZeneca, Novo Nordisk, AbbVie, Bayer, Takeda, Cardiorentis, and Pharmacosmos. Dr Anker reported receiving fees from Abbott, Bayer, Boehringer Ingelheim, Cardiac Dimension, Impulse Dynamics, Novartis, Occlutech, Servier, and Vifor Pharma and grant support from Abbott and Vifor Pharma. Dr. Bhatt discloses the following relationships: serving on the advisory board for AngioWave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys; serving on the board of directors for AngioWave (stock options), Boston Veterans Affairs Research Institute, Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock), Society of Cardiovascular Patient Care, TobeSoft; serving as chair for the American Heart Association Quality Oversight Committee (inaugural chair); serving as a consultant for Broadview Ventures; serving on the data monitoring committees for Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute, Rutgers University (for the National Institutes of Health–funded MINT trial); receiving honoraria from the American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor; associate editor), K2P (cochair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (course director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees), Wiley (steering committee); serving as deputy editor for Clinical Cardiology, chair for the NCDR-ACTION Registry Steering Committee, chair for the VA CART Research and Publications Committee; holding patents for sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women’s Hospital who assigned to Lexicon; neither Dr Bhatt nor Brigham and Women’s Hospital receive any income from this patent); receiving research funding from Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio; receiving royalties from Elsevier (editor, Braunwald’s Heart Disease); serving as site coinvestigator for Abbott, Biotronik, Boston Scientific, Cardiovascular Systems Incorporated, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; serving as trustee for American College of Cardiology; and conducting unfunded research for FlowCo, Takeda. Dr Udell reported speaker/consulting honoraria from Amgen, Boehringer Ingelheim, Janssen, Merck, Novartis, and Sanofi; grant support to his institutions from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Novartis, and Sanofi; personal fees from AstraZeneca and GlaxoSmithKline outside the submitted work. Dr Hernandez reported research grants from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Merck, Novartis, and Verily and consulting fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Myokardia, Novo Nordisk. Dr Jones reported research grants from Agency for Healthcare Research and Quality, Amgen, Bayer, Boehringer Ingelheim, American Regent, Doris Duke Charitable Foundation, Merck National Institutes of Health, Patient-Centered Outcomes Research Institute, Verily; honoraria or other support from Bayer, Bristol Myers Squibb, and Janssen Pharmaceuticals; and personal fees from AstraZeneca, Boston Scientific, Cytokinetics, and Bristol Myers Squibb outside the submitted work. Dr Butler reports serving as a consultant to Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Berlin Cures, Boehringer Ingelheim, Bristol Myers b, CVRx, G3 Pharmaceutical, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Occlutech, Relypsa, Roche, Sanofi, SC Pharma, V-Wave Limited, and Vifor. No other disclosures were reported.
1.Degli Esposti
L , Perrone
V , Veronesi
C , Buda
S , Rossini
R ; Local Health Unit group. All-cause mortality, cardiovascular events, and health care costs after 12 months of dual platelet aggregation inhibition after acute myocardial infarction in real-world patients: findings from the Platelet-Aggregation Inhibition: Persistence With Treatment and Cardiovascular Events in Real World (PIPER) study.
Vasc Health Risk Manag. 2018;14:383-392. doi:
10.2147/VHRM.S162004PubMedGoogle ScholarCrossref 2.Desta
L , Jernberg
T , Spaak
J , Hofman-Bang
C , Persson
H . Risk and predictors of readmission for heart failure following a myocardial infarction between 2004 and 2013: a Swedish nationwide observational study.
Int J Cardiol. 2017;248:221-226. doi:
10.1016/j.ijcard.2017.05.086PubMedGoogle ScholarCrossref 3.Pfeffer
MA , Claggett
B , Lewis
EF ,
et al; PARADISE-MI Investigators and Committees. Angiotensin receptor-neprilysin inhibition in acute myocardial infarction.
N Engl J Med. 2021;385(20):1845-1855. doi:
10.1056/NEJMoa2104508PubMedGoogle ScholarCrossref 4.Khot
UN , Jia
G , Moliterno
DJ ,
et al. Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification.
JAMA. 2003;290(16):2174-2181. doi:
10.1001/jama.290.16.2174PubMedGoogle ScholarCrossref 6.Hall
TS , von Lueder
TG , Zannad
F ,
et al; High-Risk Myocardial Infarction Database Initiative investigators. Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction.
Am Heart J. 2019;215:83-90. doi:
10.1016/j.ahj.2019.06.004PubMedGoogle ScholarCrossref 7.Wu
AH , Parsons
L , Every
NR , Bates
ER ; Second National Registry of Myocardial Infarction. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2).
J Am Coll Cardiol. 2002;40(8):1389-1394. doi:
10.1016/S0735-1097(02)02173-3PubMedGoogle ScholarCrossref 10.Ezekowitz
JA , Kaul
P , Bakal
JA , Armstrong
PW , Welsh
RC , McAlister
FA . Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction.
J Am Coll Cardiol. 2009;53(1):13-20. doi:
10.1016/j.jacc.2008.08.067PubMedGoogle ScholarCrossref 12.Amsterdam
EA , Wenger
NK , Brindis
RG ,
et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
J Am Coll Cardiol. 2014;64(24):e139-e228. doi:
10.1016/j.jacc.2014.09.017PubMedGoogle ScholarCrossref 13.O’Gara
PT , Kushner
FG , Ascheim
DD ,
et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
J Am Coll Cardiol. 2013;61(4):e78–e140. doi:
10.1161/CIR.0b013e3182742cf6PubMedGoogle ScholarCrossref 14.Køber
L , Torp-Pedersen
C , Carlsen
JE ,
et al; Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction.
N Engl J Med. 1995;333(25):1670-1676. doi:
10.1056/NEJM199512213332503PubMedGoogle ScholarCrossref 15.The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure.
Lancet. 1993;342(8875):821-828.
PubMedGoogle Scholar 16.Pfeffer
MA , Braunwald
E , Moyé
LA ,
et al; the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. results of the survival and ventricular enlargement trial.
N Engl J Med. 1992;327(10):669-677. doi:
10.1056/NEJM199209033271001PubMedGoogle ScholarCrossref 17.Swedberg
K , Held
P , Kjekshus
J , Rasmussen
K , Rydén
L , Wedel
H . Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II).
N Engl J Med. 1992;327(10):678-684. doi:
10.1056/NEJM199209033271002PubMedGoogle ScholarCrossref 19.First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1.
Lancet. 1986;2(8498):57-66.
PubMedGoogle Scholar 20.Pitt
B , Remme
W , Zannad
F ,
et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
N Engl J Med. 2003;348(14):1309-1321. doi:
10.1056/NEJMoa030207PubMedGoogle ScholarCrossref 22.Yusuf
S , Pitt
B , Davis
CE , Hood
WB , Cohn
JN ; SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
N Engl J Med. 1991;325(5):293-302. doi:
10.1056/NEJM199108013250501PubMedGoogle ScholarCrossref 23.Yusuf
S , Pitt
B , Davis
CE , Hood
WB
Jr , Cohn
JN ; SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.
N Engl J Med. 1992;327(10):685-691. doi:
10.1056/NEJM199209033271003PubMedGoogle ScholarCrossref 26.Hjalmarson
A , Goldstein
S , Fagerberg
B ,
et al; MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF).
JAMA. 2000;283(10):1295-1302. doi:
10.1001/jama.283.10.1295PubMedGoogle ScholarCrossref 27.Packer
M , Fowler
MB , Roecker
EB ,
et al; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.
Circulation. 2002;106(17):2194-2199. doi:
10.1161/01.CIR.0000035653.72855.BFPubMedGoogle ScholarCrossref 28.Chen
ZM , Pan
HC , Chen
YP ,
et al; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Lancet. 2005;366(9497):1622-1632. doi:
10.1016/S0140-6736(05)67661-1PubMedGoogle ScholarCrossref 32.McMurray
JJV , Packer
M , Desai
AS ,
et al; PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective Comparison of ARNI with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
Eur J Heart Fail. 2014;15(9):1062-1073. doi:
10.1093/eurjhf/hft052PubMedGoogle ScholarCrossref 33.The SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD)—rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction.
Am J Cardiol. 1990;66(3):315-322. doi:
10.1016/0002-9149(90)90842-OPubMedGoogle ScholarCrossref 34.Zannad
F , McMurray
JJV , Drexler
H ,
et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Eur J Heart Fail. 2010;12(6):617-622. doi:
10.1093/eurjhf/hfq049PubMedGoogle ScholarCrossref 36.Yusuf
S , Pfeffer
MA , Swedberg
K ,
et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
Lancet. 2003;362(9386):777-781. doi:
10.1016/S0140-6736(03)14285-7PubMedGoogle ScholarCrossref 37.Cleland
JGF , Tendera
M , Adamus
J , Freemantle
N , Polonski
L , Taylor
J ; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study.
Eur Heart J. 2006;27(19):2338-2345. doi:
10.1093/eurheartj/ehl250PubMedGoogle ScholarCrossref 39.Solomon
SD , McMurray
JJV , Anand
IS ,
et al; PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.
N Engl J Med. 2019;381(17):1609-1620. doi:
10.1056/NEJMoa1908655PubMedGoogle ScholarCrossref 40.Babaev
A , Frederick
PD , Pasta
DJ , Every
N , Sichrovsky
T , Hochman
JS ; NRMI Investigators. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock.
JAMA. 2005;294(4):448-454. doi:
10.1001/jama.294.4.448PubMedGoogle ScholarCrossref 41.Fox
CS , Muntner
P , Chen
AY , Alexander
KP , Roe
MT , Wiviott
SD . Short-term outcomes of acute myocardial infarction in patients with acute kidney injury: a report from the National Cardiovascular Data Registry.
Circulation. 2012;125(3):497-504. doi:
10.1161/CIRCULATIONAHA.111.039909PubMedGoogle ScholarCrossref 43.Hohnloser
SH , Kuck
KH , Dorian
P ,
et al; DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.
N Engl J Med. 2004;351(24):2481-2488. doi:
10.1056/NEJMoa041489PubMedGoogle ScholarCrossref 45.Kusumoto
FM , Calkins
H , Boehmer
J ,
et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials.
Circulation. 2014;130(1):94-125. doi:
10.1161/CIR.0000000000000056PubMedGoogle ScholarCrossref 51.McMurray
JJV , Solomon
SD , Inzucchi
SE ,
et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction.
N Engl J Med. 2019;381(21):1995-2008. doi:
10.1056/NEJMoa1911303PubMedGoogle ScholarCrossref 52.McMurray
JJV , DeMets
DL , Inzucchi
SE ,
et al; DAPA-HF Committees and Investigators. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
Eur J Heart Fail. 2019;21(5):665-675. doi:
10.1002/ejhf.1432PubMedGoogle ScholarCrossref 53.Tromp
J , Ponikowski
P , Salsali
A ,
et al. Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial.
Eur J Heart Fail. 2021;23(5):826-834. doi:
10.1002/ejhf.2137PubMedGoogle ScholarCrossref 57.Solomon
SD , de Boer
RA , DeMets
D ,
et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
Eur J Heart Fail. 2021;1(23):1217-1225. doi:
10.1002/ejhf.2249PubMedGoogle ScholarCrossref 59.Anker
SD , Butler
J , Filippatos
GS ,
et al; EMPEROR-Preserved Trial Committees and Investigators. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Eur J Heart Fail. 2019;21(10):1279-1287. doi:
10.1002/ejhf.1596PubMedGoogle ScholarCrossref 60.Xie
Y , Bowe
B , Gibson
AK , McGill
JB , Maddukuri
G , Al-Aly
Z . Clinical implications of estimated glomerular filtration rate dip following sodium-glucose cotransporter-2 inhibitor initiation on cardiovascular and kidney outcomes.
J Am Heart Assoc. 2021;10(11):e020237. doi:
10.1161/JAHA.120.020237PubMedGoogle ScholarCrossref